# FDA recall D-0119-2025

> **Viatris Inc** · Class II · drug recall initiated 2024-11-18.

## Product

Levothyroxine Sodium Tablets USP, 137 mcg, packaged in a) 90-count bottles (NDC 0378-1823-77) and b) 1000-count bottles (NDC 0378-1823-10), Rx only, Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A.

## Reason for recall

Superpotent Drug and Subpotent Drug: potency failures obtained

## Distribution

Nationwide within the United States and Puerto Rico

## Key facts

- **Recall number:** D-0119-2025
- **Recalling firm:** Viatris Inc
- **Classification:** Class II
- **Product type:** drug
- **Status:** Ongoing
- **Initiation date:** 2024-11-18
- **Report date:** 2024-12-18

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** Canonsburg, PA, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0119-2025

## Citation

> AI Analytics. FDA recall D-0119-2025. Retrieved 2026-06-02 from https://api.ai-analytics.org/recall/D-0119-2025. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*